Cargando…

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()

The global incidence of nonalcoholic fatty liver disease (NAFLD) is mounting incessantly, and it is emerging as the most frequent cause of chronic and end stage liver disorders. It is the starting point for a range of conditions from simple steatosis to more progressive nonalcoholic steatohepatitis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vachher, Meenakshi, Bansal, Savita, Kumar, Bhupender, Yadav, Sandeep, Burman, Archana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589178/ https://www.ncbi.nlm.nih.gov/pubmed/36299516 http://dx.doi.org/10.1016/j.heliyon.2022.e11119

Ejemplares similares

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

Effect of exercise and diet intervention in NAFLD and NASH via GAB2 methylation
por: Wu, Na, et al.
Publicado: (2021)

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
por: Ohtani, Naoko, et al.
Publicado: (2023)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Advanced glycation end products: Key mediator and therapeutic target of cardiovascular complications in diabetes
por: Bansal, Savita, et al.
Publicado: (2023)

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations
por: Adinolfi, Luigi Elio, et al.
Publicado: (2016)

Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
por: Svegliati-Baroni, Gianluca, et al.
Publicado: (2020)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
por: Piras, Cristina, et al.
Publicado: (2021)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
por: Finotti, Michele, et al.
Publicado: (2021)

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
por: Kořínková, L., et al.
Publicado: (2020)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Involvement of Intracellular TAGE and the TAGE–RAGE–ROS Axis in the Onset and Progression of NAFLD/NASH
por: Sakasai-Sakai, Akiko, et al.
Publicado: (2023)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review
por: Kan Changez, Mah I, et al.
Publicado: (2023)

Deciphering Streptococcal Biofilms
por: Yadav, Puja, et al.
Publicado: (2020)

Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
por: Vilalta, Adrian, et al.
Publicado: (2022)

Deciphering the role of DNA methylation in multiple sclerosis: emerging issues
por: Sokratous, Maria, et al.
Publicado: (2016)

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH
por: Hydes, Theresa J., et al.
Publicado: (2020)

Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis
por: Plaza-Díaz, Julio, et al.
Publicado: (2021)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
por: Kim, Hyunmi, et al.
Publicado: (2021)

SAT-LB004 Therapeutic Potential of LPCN 1144 in NAFLD and NASH
por: Baker, Jonathan, et al.
Publicado: (2019)

Non-Invasive Risk Stratification in NAFLD/NASH Patients for Screening EGD
por: Romano, John, et al.
Publicado: (2022)

Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction
por: Guo, Mingwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rspqurhcbmfgnt229q9nlebm4g